A5108138230- Sirtuins and Resveratrol in Medicine
- Inflammatory Bowel Disease
- Autoimmune and Inflammatory Disorders Research
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Microscopic Colitis
- RNA and protein synthesis mechanisms
- Liver Diseases and Immunity
- Genomics, phytochemicals, and oxidative stress
- RNA modifications and cancer
- Helicobacter pylori-related gastroenterology studies
- Adipose Tissue and Metabolism
- Biochemical and Molecular Research
- Genetic Associations and Epidemiology
- Retinoids in leukemia and cellular processes
- RNA Interference and Gene Delivery
- CRISPR and Genetic Engineering
- Dermatological diseases and infestations
- Vector-borne infectious diseases
- Cancer-related Molecular Pathways
- Cancer-related molecular mechanisms research
- Antioxidant Activity and Oxidative Stress
- Fungal Biology and Applications
- Cancer, Hypoxia, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
Pfizer (United States)
2017-2025
Cardiovascular Institute of the South
2018-2025
Shanghai Innovative Research Center of Traditional Chinese Medicine
2025
Shanghai Skin Disease Hospital
2025
Tongji University
2025
Kunming Medical University
2025
Innovation Team (China)
2025
Stanford University
2015-2025
China Medical University
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study enrolled aged ≥18 years diagnosed AS, meeting modified New York criteria, centrally read radiographs, and an inadequate response or intolerance to ≥2 non-steroidal anti-inflammatory drugs. Patients were randomised 1:1 receive 5 mg two times per day placebo for 16 weeks. After week 16, all received...
Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients rheumatoid arthritis (RA) or without a history atherosclerotic disease (ASCVD) ORAL Surveillance.
To evaluate malignancies and their associations with baseline risk factors cardiovascular scores tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients rheumatoid arthritis (RA).In an open-label, randomised controlled trial (ORAL Surveillance; NCT02092467), 4362 RA aged ≥50 years ≥1 additional received 5 (N=1455) or 10 mg two times per day (N=1456) TNFi (N=1451). Incidence rates (IRs; first events/100 patient-years) HRs were calculated for adjudicated excluding non-melanoma...
Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report integrated summary tofacitinib safety from completed global UC clinical program (9.2 years maximum exposure).
Resveratrol has been shown to have chemopreventive, cardioprotective, and antiaging properties. Here, we report that resveratrol is a potent inhibitor of quinone reductase 2 (QR2) activity in vitro with dissociation constant 35 nM show it specifically binds the deep active-site cleft QR2 using high-resolution structural analysis. All three hydroxyl groups form hydrogen bonds amino acids from QR2, anchoring flat molecule parallel isoalloxazine ring FAD. The unique pocket could potentially...
Infection with the agent of human granulocytic ehrlichiosis occurs in areas which Borrelia burgdorferi and Babesia microti are endemic.1–4 The most likely vector is deer tick, Ixodes scapularis, also Lyme disease babesiosis.3,4 Coinfection humans both B. can be anticipated because ixodes ticks infected two organisms have been identified several locales.3–5 diagnosis simultaneous infection important natural history . . .
Proliferation of pulmonary arterial smooth muscle cells, endothelial dysfunction, oxidative stress, and inflammation promotes the development hypertension. Resveratrol is a polyphenolic compound that exerts antioxidant anti-inflammatory protective effects in systemic circulation, but its on arteries remain poorly defined. The present study was undertaken to investigate efficacy resveratrol prevent Rats injected with monocrotaline progressively developed treatment (25 mg/kg per day, PO, from...
Programmed cell death ligand 1 (PD‑L1) expressed in cancer cells interacting with its receptor programmed (PD‑1) immune represents a regulatory axis linked to the suppression and evasion of host functions. The blockade PD‑1/PD‑L1 interaction using monoclonal antibodies has emerged as an effective therapy for several solid tumors; however, durable response been observed subset patients PD‑L1-positive tumors. Thus, understanding mechanisms responsible expression PD‑L1 tumor may help improve...
Abstract Background and Aims Pivotal trials in ulcerative colitis have historically excluded patients with isolated proctitis. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active colitis. This post hoc analysis assessed efficacy safety etrasimod 2 mg once daily proctitis (centrally read) from phase 3 ELEVATE UC 52 12 trials. Methods Patients, including those (<10 cm rectal involvement) who met...
Two different mechanisms are considered to be the primary cause of aging. Cumulative DNA damage caused by reactive oxygen species (ROS), by-products oxidative phosphorylation, is one these (ROS concept). Constitutive stimulation mitogen- and nutrient-sensing mTOR/S6 signaling second mechanism (TOR The flow- laser scanning- cytometric methods were developed measure level constitutive damage/ROS- as well mTOR/S6- in individual cells. Specifically, persistent activation ATM expression γH2AX...
Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). Patient-reported outcomes (PROs) were evaluated in patients with PsA inadequate responses to tumour necrosis factor inhibitors (TNFi-IR) a 6-month, phase III randomised controlled trial (OPAL Beyond [NCT01882439]).Patients (N=394) received tofacitinib 5 or 10 mg twice daily placebo (advancing at month 3). Least squares mean changes from baseline and percentages reporting improvements ≥minimum clinically...